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Left lobe living donor liver transplants- expected or from left field?
Patient safety has always been at the centre of living donor liver transplantation (LDLT). On one hand, 
there is concern over the safety of the healthy donor and, on the other, the concern over the safety of a 
recipient with chronic liver disease receiving a fractional graft. Well publicized donor deaths, particularly 
the sad death of donor Mike Hurewitz in 2002 at Mount Sinai Hospital, brought the risks of adult LDLT 
into very sharp focus. Coupled with this, new knowledge and techniques for dealing with small for size 
syndrome have opened the door to the use of potentially smaller liver grafts with lower risks for donors 
while maintaining safety for recipients. In this month’s edition of HPB, Saidi and colleagues have reviewed 
the growth of left lobe adult LDLT in the USA over the past 14 years. Left lobe LDLT is more complex 
in terms of vascular reconstruction and requires longer hospital stay for the recipients but is increasing 
in popularity in the USA. The recipients tend to be smaller and are more likely female but this appears 
to be a useful source of grafts. Saidi et al. recommend that left adult LDLT should be protocol-directed 
and advocate further investigation of its potential. Newer technology and a greater understanding of liver 
regeneration may mean that even smaller grafts such as segment 2 & 3 grafts could be used in the context 
of auxillary liver transplantation in adults and a very small number of these procedures have already been 
performed.
Stephen J Wigmore
When good intentions go unrewarded
With today’s improved imaging and clinical staging techniques, most unresectable pancreatic cancer 
(UnR-PCa) patients are identified preoperatively. For some, however, surgery is still required. What 
should be done at laparotomy when UnR-PCa is found? Lyons et al. from Memorial Sloan-Kettering 
Cancer Center identified 157 such patients over a recent 10 year period. They compared clinical outcomes 
including complications, interventions and days in-hospital among various procedures performed with 
palliative intent. Bypass procedures were performed in 79% of patients, most often as combined biliary-
duodenal bypass (38%), and these were usually not influenced by established degrees of obstruction. In 
21% of patients, the abdomen was closed after determining unresectability. Post-operative chemotherapy/
radiation therapy was given to 73% of patients. Median overall survival was 11 months. Ultimately, 
72 patients (45%) underwent 212 additional disease-related procedures, of which 15 (10%) were re-
operations. Complications (30-day) occurred in 44 (28%) patients, and more often when established 
obstructions were not initially bypassed. There were 3 peri-operative deaths. Re-admissions occurred for 
91 (58%) of patients and were least frequent following double bypass. Regardless of procedure, patients 
spent on average 16 days in-hospital prior to death. Other key outcomes such as ability to complete 
further treatments and overall quality of life are not reported. While this study cannot render guideline 
recommendations for the treatment of UnR-PCa, it does reveal that a surgeon’s palliative intent is not 
always rewarded. An individualized approach remains best for these patients, and should always include 
realistic considerations of expectations and risks.
Mark Callery
Portal vein embolisation following chemotherapy and bevacizumab
Simoneau et al. present an excellent retrospective case-control study of 109 patients with colorectal liver 
metastases who underwent six cycles of chemotherapy with or without bevacizumab followed by portal 
vein embolisation and compared these to a small group of controls (n = 11) who did not receive portal 
vein embolisation but did receive bevacizumab. The authors performed pre- and postembolisation volu-
metry on not only the future liver remnant but the tumors themselves. The important findings of this 
study confirmed that portal vein embolisation resulted in a significant increase in tumour volume in both 
the embolised and nonembolised lobe. In addition, there was a nonsignificant difference in the appear-
ance of new disease in the nonembolised lobe in those who underwent portal vein embolisation as 
compared to controls. In those who received bevacizumab with the chemotherapy regimen prior to portal 
vein embolisation there appeared to be retardation in the degree of tumour growth in both lobes follow-
ing portal vein embolisation, however, despite the sample sizes being of reasonable size, these marked 
reductions were not statistically different. This suggests a wide range of spread within the data and is 
likely to indicate that other factors that are yet to be elucidated played an important role. As the authors 
allude to in their discussion, long term outcomes looking at survival and patterns of recurrence for those 
patients who have undergone portal vein embolisation will be important to determine its true value. At 
this point it would seem that portal vein embolisation should be used carefully and judiciously, specifi-
cally limiting it in those patients who truly have unresectable disease due to an insufficient liver remnant.
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